Adult hepatocellular carcinoma (HCC) is a primary liver cancer that starts from the main liver cells called hepatocytes. It most often grows in a liver that has long-term damage, especially cirrhosis. HCC can appear as a single lump, many small lumps, or spread through the liver. Doctors often find it using special liver scans that show a typical pattern: the tumor lights up with blood in the early scan phase and fades in later phases. HCC can stay silent for a long time. When it grows, people may notice weight loss, pain in the upper right belly, a swollen abdomen, or yellow eyes and skin. Early finding makes treatment stronger and safer. Treatments include surgery, liver transplant, heating or freezing the tumor, blocking its blood supply, radiation, and drugs that target the cancer or boost the immune system. Over time, preventing or treating hepatitis B and C, avoiding alcohol harm, and reducing fatty liver greatly lowers the chance of HCC. (Overview and risk factors supported by NCI and WHO resources. Cancer.gov+1World Health Organization)
Adult hepatocellular carcinoma (HCC) is the most common primary liver cancer. It starts from the main liver cells, called hepatocytes. Most people who develop HCC already have long-term liver damage. This long-term damage is from hepatitis B or C infection, alcohol-related liver disease, or fatty liver disease. HCC often grows silently for years because the liver can still work when parts of it are sick. Doctors can sometimes diagnose HCC by special imaging alone, without a biopsy, when a classic pattern appears on contrast CT or MRI—bright in the arterial phase and darker (“washout”) later. Today we treat HCC with a mix of surgery, liver transplant, local liver-directed procedures, and modern cancer drugs, including immune therapy. Screening people at high risk every 6 months helps find tumors earlier when cures are still possible. PMChepatitisc.uw.edu
Hepatocellular carcinoma is a cancer that begins in the liver itself. It usually appears after many years of inflammation and scarring, known as cirrhosis. The main drivers are chronic hepatitis B or C infection, heavy alcohol use, obesity with diabetes and fatty liver, and exposure to aflatoxin (a toxin from mold on poorly stored grains and nuts). In people with cirrhosis or chronic hepatitis B, doctors look carefully for HCC because the risk is higher. Diagnosis can be made without biopsy when the scan shows the “signature” pattern. Treatment depends on tumor size and number, whether cancer has spread, and how well the rest of the liver works. Options include surgical removal, liver transplant for select cases, local procedures like heat ablation, chemoembolization, or radiation into the liver artery, and medicines that block tumor blood supply or awaken the immune system to fight cancer. Screening with ultrasound and a blood test called AFP every 6 months in high-risk people increases the chance of catching cancer early. PMC+1hepatitisc.uw.edu
Another names
Hepatocellular carcinoma is also called HCC. Older texts may use the word “hepatoma,” but most experts now avoid it because it sounds like a benign tumor; HCC is malignant. You may also hear “primary liver cancer” when the cancer starts in the liver itself (not spread from somewhere else). Fibrolamellar carcinoma is a special subtype that usually happens in younger people without cirrhosis and is discussed under “Types.” (Synonyms reference. Cancer Research UK)
Types
By how it looks and grows in the liver
Solitary HCC: one main mass. This can be removed by surgery if liver function is good and blood vessels are clear.
Multifocal HCC: more than one lump in different parts of the liver.
Diffuse/infiltrative HCC: cancer threads through the liver tissue and is harder to remove.
By microscope (pathology)
Conventional HCC: the common form made of malignant hepatocytes.
Clear-cell, steatohepatitic, scirrhous, macro-trabecular-massive and other patterns: these describe how the cells look and the stroma around them. Pathologists use special stains (for example glypican-3, heat-shock protein-70, glutamine synthetase) to confirm HCC when scans are not typical.
Fibrolamellar carcinoma: occurs in younger adults, often without cirrhosis; cells are separated by fibrous bands.
By staging system (used to plan care)
Doctors commonly use BCLC staging (Barcelona Clinic Liver Cancer). It considers tumor size and number, liver function, and the person’s overall fitness to select the best treatment. (Staging/diagnosis approach reflected in AASLD/EASL guidance and LI-RADS framework. PMCJournal of Hepatology)
Causes
Chronic hepatitis B virus (HBV). HBV can live in the liver for years and damage DNA, leading to cancer even without cirrhosis. Vaccination and antiviral treatment reduce risk but do not erase it. World Health OrganizationScienceDirect
Chronic hepatitis C virus (HCV). Long-standing HCV causes inflammation and scarring that can end in cirrhosis and HCC. Cure with direct-acting antivirals lowers risk, but people with cirrhosis still need regular checks. Cancer.gov
Cirrhosis of any cause. Cirrhosis is advanced scarring. It creates a high-risk setting where abnormal cells can grow into HCC. Alcohol, viral hepatitis, fatty liver, and other diseases can all lead to cirrhosis. Cancer.gov
Alcohol-related liver disease. Years of heavy drinking injure the liver, cause cirrhosis, and raise HCC risk, especially with HBV or HCV. PMC
Metabolic dysfunction-associated fatty liver disease (often called NAFLD/MASLD) and NASH. Fat and inflammation in the liver (linked to obesity and insulin resistance) can progress to cirrhosis and HCC. Cancer.gov
Aflatoxin exposure. This toxin from moldy grains and nuts can damage liver DNA. Risk is highest where food storage is poor and when HBV is also present (strong synergy). PMCIARC Publications
Type 2 diabetes. Diabetes and insulin resistance increase fatty liver and inflammation, which raise HCC risk. PMC
Obesity. Extra body fat promotes fatty liver and NASH, which lead to cirrhosis and HCC. Cancer.gov
Hereditary hemochromatosis. Iron overload scars the liver and strongly raises HCC risk, especially after cirrhosis develops. Cancer.gov
Alpha-1 antitrypsin deficiency. Abnormal protein builds up in liver cells and can cause cirrhosis and HCC. NCBI
Wilson disease. Copper overload injures the liver, can cause cirrhosis, and raises HCC risk. NCBI
Autoimmune hepatitis. The immune system attacks the liver, which can end in cirrhosis and HCC if not controlled. NCBI
Primary biliary cholangitis (advanced). Long-term bile duct injury can lead to cirrhosis; the main liver cancer risk rises once cirrhosis is present. NCBI
Chronic smoking (with other risks). Smoking adds stress on the liver and may worsen risk, especially with alcohol or viral hepatitis. PMC
Long-term immunosuppression or HIV co-infection with viral hepatitis. Weaker immune control and faster fibrosis raise HCC risk. NCBI
Family history of HCC. Shared genes and shared exposures increase a person’s baseline risk. NCBI
Male sex and older age. Hormones and lifetime exposures make HCC more common in men and older adults. Cancer.gov
Aflatoxin-HBV synergy in high-exposure regions. When both are present, risk multiplies, not just adds. ScienceDirect
Porphyria cutanea tarda and some rare metabolic diseases. These can injure the liver over many years and increase cancer risk. NCBI
Arsenic or other environmental toxins (region-specific). Certain contaminants injure the liver and may raise HCC risk; aflatoxin is the clearest toxin linked to HCC. Lippincott Journals
Symptoms
No symptoms at first. Early HCC can be silent. This is why high-risk people need regular liver scans and AFP blood tests. (Surveillance emphasis from major guidelines. Cancer.gov)
Tiredness and weakness. Cancer and poor liver function both drain energy.
Unplanned weight loss. The body burns calories and muscle during chronic illness and cancer.
Loss of appetite and early fullness. A large liver or fluid in the belly can press on the stomach.
Upper right belly pain or discomfort. The liver has a capsule; stretching it causes a dull ache.
Swollen abdomen (ascites). Fluid collects when the scarred liver cannot handle blood flow.
Yellow eyes/skin (jaundice). Bile cannot drain well through the damaged liver.
Itchy skin and dark urine. Bile salts and pigments build up in the blood.
Fever or night sweats. Some tumors and infections trigger inflammatory signals.
Nausea or vomiting. Poor liver function and pressure effects can upset the stomach.
Enlarged liver (hepatomegaly). A doctor may feel a firm or nodular edge under the right ribs.
Enlarged spleen (splenomegaly). Portal vein pressure rises and the spleen grows.
Leg swelling. Low albumin and high venous pressure cause fluid to leak into tissues.
Confusion or sleepiness (hepatic encephalopathy). Toxins build up when the liver fails to clear them.
Bone or shoulder pain, cough, or shortness of breath when cancer spreads to bone or lung.
Diagnostic tests
Important note: In adults with cirrhosis or chronic HBV, doctors often diagnose HCC without biopsy if contrast CT or MRI shows a classic pattern: arterial phase hyper-enhancement and washout later, sometimes with a capsule. Radiologists use LI-RADS, a standard system to label how likely a mass is HCC. (Core principle from AASLD/LI-RADS and systematic review. PMCAASLD)
A) Physical examination
General inspection and vital signs. Doctors look for jaundice, weight loss, fever, and check pulse and blood pressure. These signs suggest liver stress or infection but do not prove cancer.
Abdominal inspection. A bulging abdomen, visible veins, or scars signal chronic liver disease.
Abdominal palpation and percussion. A firm, enlarged, or nodular liver edge suggests tumor or cirrhosis. Tenderness suggests stretching of the liver capsule.
Stigmata of chronic liver disease. Spider veins on the skin, red palms, muscle wasting, or breast enlargement in men point to long-term hormone and protein changes from liver failure.
B) Manual bedside maneuvers and simple procedures
Shifting dullness (for ascites). Tapping the belly in different positions shows fluid movement. Ascites supports advanced liver disease.
Fluid wave/“fluid thrill.” A wave across the abdomen suggests a large volume of fluid.
Castell’s or splenic percussion sign. Change in percussion note with breathing can suggest an enlarged spleen from portal hypertension.
Diagnostic paracentesis (ascitic tap). A thin needle removes a small sample of fluid to test protein, albumin, and infection (SBP). It does not diagnose the tumor but guides safe treatment.
C) Laboratory and pathological tests
Liver panel (ALT, AST, ALP, GGT, bilirubin, albumin). These show injury, blockage, and the liver’s protein-making power.
Clotting tests (PT/INR). Poor liver function raises INR; doctors need this number to plan any procedure.
Serum alpha-fetoprotein (AFP). A tumor marker made by some HCCs. It can be high in cancer but also rises in other liver diseases. It helps screen and monitor, not by itself diagnose. NCBI
AFP-L3% and des-gamma-carboxy prothrombin (DCP/PIVKA-II). These refined markers can improve detection and risk assessment when used with imaging. NCBI
Viral hepatitis tests. HBsAg and HBV DNA (for hepatitis B), anti-HCV and HCV RNA (for hepatitis C) confirm cause and future risk and guide treatment. Cancer.gov
Liver biopsy (when imaging is not typical). A tiny core of tissue is taken with a needle to look under a microscope. Pathologists may use glypican-3 and other stains to confirm HCC. Biopsy is avoided if imaging is conclusive because of bleeding and seeding risks. (Role of biopsy reflected in guidelines. AASLD)
D) Electrodiagnostic/physiologic tests
Electrocardiogram (ECG). This checks heart rhythm and heart health before surgery, transplant, or certain drugs. It does not diagnose the tumor but keeps treatment safe.
Electroencephalogram (EEG) in selected patients with confusion. Rarely used; helps rule out seizures and supports the diagnosis of hepatic encephalopathy when mental status changes are unclear.
E) Imaging tests
Abdominal ultrasound (US). This is the usual first scan. It can spot a mass and guide the next steps. In high-risk people, US is used regularly for surveillance. Cancer.gov
Contrast-enhanced multiphasic CT of the liver. CT takes images in arterial, portal-venous, and delayed phases. HCC often enhances early and washes out later. This pattern can confirm HCC in the right setting. AASLD
Contrast-enhanced MRI of the liver (with LI-RADS reporting). MRI shows the blood flow pattern and subtle features (like a capsule or fat). It is highly accurate for HCC diagnosis and staging. PMC
Contrast-enhanced ultrasound (CEUS) and Doppler. CEUS can show quick arterial filling and washout in real time. Doppler checks blood flow, including portal vein tumor thrombus, which affects treatment choice. (Imaging role summarized in guidance. AASLD)
Non-pharmacological treatments
Supervised aerobic walking program
Description. A gentle, progressive walking plan (for example, 20–30 minutes, 3–5 days per week) is safe for most adults with stable liver disease and HCC under treatment. Sessions start at a pace that allows comfortable conversation. Intensity is increased slowly, guided by breathlessness and fatigue scales. Include warm-up and cool-down. People with portal hypertension, anemia, or on beta-blockers should review a plan with their clinician first.
Purpose. Reduce fatigue, improve stamina, mood, and appetite.
Mechanism. Regular aerobic activity improves oxygen delivery, mitochondrial function, insulin sensitivity, and inflammatory signaling.
Benefits. Better quality of life, less cancer-related fatigue, improved physical function; may help people tolerate therapy. PMCPubMedLight resistance training (bands or body-weight)
Description. Two to three non-consecutive days per week focusing on major muscle groups with elastic bands, light dumbbells, or body-weight moves (sit-to-stand, wall push-ups). Sets are short (8–12 reps), with long rests and close attention to form and dizziness.
Purpose. Preserve or rebuild muscle mass and strength lost from cancer, cirrhosis, or inactivity.
Mechanism. Stimulates muscle protein synthesis and neuromuscular activation; counters sarcopenia.
Benefits. Stronger legs and core for safe walking, reduced falls, easier daily living; often improves fatigue and mood. PMCFlexibility and joint mobility sessions
Description. Gentle daily stretching (5–10 minutes) for hamstrings, calves, hip flexors, chest, and shoulders; add shoulder circles and ankle pumps.
Purpose. Reduce stiffness, maintain joint range, and ease aches that limit activity.
Mechanism. Improves soft-tissue extensibility and neural tolerance to stretch.
Benefits. Smoother walking, better posture, less discomfort during rest and therapy days.Balance and fall-prevention drills
Description. Simple home drills like tandem stance, single-leg holds near a countertop, and sit-to-stand practice; 10–15 minutes daily.
Purpose. Prevent falls in patients weakened by illness, anemia, or medicines.
Mechanism. Trains proprioception and lower-limb neuromuscular control.
Benefits. Increased safety and confidence; fewer injuries and hospital visits.Breathing exercises and pacing
Description. Diaphragmatic breathing, pursed-lip exhalation, and activity pacing (break tasks into short bouts).
Purpose. Ease breathlessness, anxiety, and fatigue spikes.
Mechanism. Lowers sympathetic overdrive; improves ventilation efficiency.
Benefits. Calmer breathing, steadier energy through the day.Post-operative physiotherapy after liver resection
Description. Early mobilization, incentive spirometry, coughing support (hug pillow), and progressive walking starting day 1–2 post-op, guided by the surgical team.
Purpose. Prevent pneumonia and deconditioning after surgery.
Mechanism. Improves lung expansion and circulation; preserves muscle.
Benefits. Fewer complications, faster return to home routines.Pelvic and core conditioning
Description. Gentle core bracing, bridges, and side-lying leg raises under supervision.
Purpose. Support spine and trunk during fatigue and abdominal discomfort.
Mechanism. Strengthens deep stabilizers; improves load transfer.
Benefits. Reduced back strain, easier transfers and walking.Lymphedema-aware limb care (if nodes treated)
Description. Education on skin care, compression as advised, and safe, gradual exercises.
Purpose. Limit limb swelling after node sampling or therapy.
Mechanism. Aids lymph flow; reduces infection risk.
Benefits. Better comfort and function.Cancer-specific exercise prescription (supervised)
Description. A tailored plan from a clinician trained in exercise oncology; integrates blood counts, portal hypertension status, and treatment cycles.
Purpose. Build a safe plan around comorbidities.
Mechanism. Personalization reduces adverse events and dropout.
Benefits. Higher adherence; better outcomes. ACSM+1Yoga (restorative or gentle hatha)
Description. Short, low-strain sessions with props; emphasize breath, gentle flows, and relaxation.
Purpose. Ease stress, improve range of motion and sleep.
Mechanism. Parasympathetic activation; reduces muscle tension.
Benefits. Lower anxiety and fatigue; better well-being.Tai chi or qigong
Description. Slow, coordinated movements 2–3 times per week.
Purpose. Improve balance, mindfulness, and calmness.
Mechanism. Integrates gentle aerobic, balance, and focused breathing.
Benefits. Better steadiness and mood.Mindfulness-based stress reduction (MBSR)
Description. Structured 8-week program of meditation, body scan, and gentle movement.
Purpose. Reduce cancer-related stress, insomnia, and pain perception.
Mechanism. Trains attention and reduces limbic reactivity.
Benefits. Improved anxiety, coping, and sleep.Cognitive behavioral therapy (CBT) for fatigue/anxiety
Description. Short, skills-based counseling to reframe unhelpful thoughts and plan energy-saving behaviors.
Purpose. Reduce fatigue disability and fear.
Mechanism. Modifies cognition-behavior loops that amplify symptoms.
Benefits. More activity and better mood.Sleep hygiene coaching
Description. Fixed wake time, dark cool bedroom, screen curfew, and pain-relief timing with clinician guidance.
Purpose. Improve restorative sleep.
Mechanism. Aligns circadian cues and reduces arousal.
Benefits. Better energy, cognition, and mood.Nutrition counseling focused on liver health
Description. Small, frequent meals high in protein (if safe for liver status), with fiber, healthy fats, and limited salt if fluid-overloaded; avoid alcohol.
Purpose. Preserve lean mass and support healing.
Mechanism. Supplies amino acids and micronutrients; stabilizes glucose.
Benefits. Stronger body, fewer admissions.Educational therapy: understanding scans and labs
Description. A nurse or educator explains what AFP, CT/MRI, and LI-RADS categories mean, and how treatment choices are made.
Purpose. Reduce fear and improve shared decisions.
Mechanism. Knowledge builds control and adherence.
Benefits. Better preparation for visits and tests. PMCRadiopaediaTreatment-cycle energy planning (“activity budgeting”)
Description. Map high- and low-energy days around infusions or TACE to time errands and rest.
Purpose. Prevent crash-and-burn fatigue cycles.
Mechanism. Matches demand to capacity.
Benefits. Smoother weeks, fewer setbacks.Symptom diary and early-alert education
Description. Daily checklist for pain, fevers, bleeding, swelling legs, confusion, and weight change; includes “when to call.”
Purpose. Catch complications early.
Mechanism. Prompts rapid triage.
Benefits. Fewer emergencies; safer care.Alcohol-cessation support
Description. Brief counseling, peer support, and, if needed, medications from a clinician.
Purpose. Remove a major liver toxin.
Mechanism. Halts progression of cirrhosis; improves candidacy for therapies.
Benefits. Better survival and treatment tolerance.Hepatitis education and vaccination counseling
Description. Teach the value of HBV vaccination for family members and close contacts, and HCV cure options for eligible people.
Purpose. Prevent new infections and reinfection risks in the community.
Mechanism. Breaks transmission; lowers population HCC.
Benefits. Public-health benefit; peace of mind. PMCNew England Journal of MedicineAflatoxin-safe food storage education
Description. Store grains and nuts dry, cool, and clean; discard moldy foods; buy from reliable sources.
Purpose. Reduce aflatoxin exposure, especially in high-risk regions.
Mechanism. Cuts ingestion of a proven liver carcinogen.
Benefits. Lower lifetime liver-cancer risk for households. PMCLippincott JournalsVaccination and infection-prevention coaching
Description. Discuss HBV vaccination for at-risk adults, safe injections, and avoiding unregulated herbal products.
Purpose. Protect remaining liver function.
Mechanism. Prevents viral injury and toxins.
Benefits. Fewer decompensation events. PMCPalliative care early integration
Description. Symptom-focused team support alongside cancer treatment (not “end-only”).
Purpose. Optimize pain, nausea, mood, and goals-of-care discussions.
Mechanism. Multidisciplinary symptom control and planning.
Benefits. Better quality of life and care coordination. ESMOCaregiver skills training
Description. Teach safe transfers, medication schedules, nutrition help, and red-flag signs.
Purpose. Reduce caregiver strain and patient risk.
Mechanism. Knowledge and routines.
Benefits. Fewer crises, more home time.Return-to-movement after locoregional therapy
Description. A step-wise plan to resume walking and light chores 24–72 hours after TACE, TARE, ablation, or SBRT as advised by the team.
Purpose. Avoid prolonged bed rest.
Mechanism. Maintains aerobic capacity and muscle.
Benefits. Faster recovery, less fatigue. PMC+2PMC+2
Drug treatments
⚠️ Doses below reflect typical labels or trial regimens; individual dosing must be set by an oncologist based on liver function, comorbidities, and local guidelines.
Atezolizumab + Bevacizumab (first-line)
Class. PD-L1 inhibitor + anti-VEGF antibody.
Dose/Time. Atezolizumab 1200 mg IV + bevacizumab 15 mg/kg IV every 3 weeks. Upper endoscopy is often advised to screen/treat varices before starting.
Purpose. Standard first-line for many unresectable HCC patients.
Mechanism. Unleashes immune attack and starves tumor by blocking blood-vessel signals.
Side effects. Immune-related inflammation (skin, bowel, liver, lung), bleeding/proteinuria/hypertension from bevacizumab. PMCScienceDirectDurvalumab + Tremelimumab (STRIDE; first-line option)
Class. PD-L1 inhibitor + CTLA-4 inhibitor (single priming dose of tremelimumab).
Dose/Time. One “priming” dose of tremelimumab plus durvalumab every 4 weeks.
Purpose. Alternative first-line for unresectable HCC.
Mechanism. Dual checkpoint blockade to expand and sustain anti-tumor T-cells.
Side effects. Immune-mediated colitis, hepatitis, endocrinopathies; monitor closely. New England Journal of Medicine EvidencePubMedNivolumab + Ipilimumab (first-line, 2025 FDA approval; also second-line earlier)
Class. PD-1 inhibitor + CTLA-4 inhibitor.
Dose/Time. Common regimen: nivo 1 mg/kg + ipi 3 mg/kg IV q3wk ×4, then nivolumab maintenance (or per updated label/trial).
Purpose. First-line option for unresectable/metastatic HCC in 2025 U.S. label; also used after prior TKIs historically.
Mechanism. Synergistic checkpoint blockade.
Side effects. Immune-related toxicities; needs expert monitoring. U.S. Food and Drug AdministrationPMCLenvatinib (first-line TKI)
Class. Multikinase inhibitor (VEGFR, FGFR, etc.).
Dose/Time. Weight-based: 12 mg daily (≥60 kg) or 8 mg daily (<60 kg) orally.
Purpose. First-line alternative when immunotherapy is unsuitable.
Mechanism. Anti-angiogenic and antiproliferative signaling blockade.
Side effects. Hypertension, fatigue, hand–foot reaction, diarrhea, appetite loss.Sorafenib (first-line/legacy TKI)
Class. Multikinase inhibitor (RAF/VEGFR/PDGFR).
Dose/Time. 400 mg orally twice daily; dose adjustments common.
Purpose. Option when other first-line regimens are not appropriate.
Mechanism. Inhibits tumor proliferation and blood-vessel growth.
Side effects. Hand–foot skin reaction, diarrhea, fatigue, hypertension.Regorafenib (second-line after sorafenib tolerance)
Class. Multikinase inhibitor.
Dose/Time. 160 mg orally daily, 3 weeks on/1 week off per 28-day cycle (adjust as needed).
Purpose. Proven survival benefit after prior sorafenib.
Mechanism. Broader anti-angiogenic and oncogenic pathway blockade.
Side effects. Hand–foot reaction, hypertension, fatigue, liver test changes. The LancetPMCCabozantinib (second/third-line)
Class. Multikinase inhibitor (MET, AXL, VEGFR2).
Dose/Time. 60 mg orally once daily (adjust per tolerance).
Purpose. Improves survival after prior therapy.
Mechanism. Targets resistance pathways and angiogenesis.
Side effects. Fatigue, diarrhea, hypertension, palmar-plantar erythrodysesthesia, liver tests. New England Journal of MedicineRamucirumab (for AFP ≥ 400 ng/mL after prior therapy)
Class. VEGFR2 antibody.
Dose/Time. 8 mg/kg IV every 2 weeks.
Purpose. Option specifically for patients with high AFP.
Mechanism. Cuts VEGF-driven blood-vessel signals.
Side effects. Hypertension, proteinuria, bleeding risk. U.S. Food and Drug AdministrationPMCPembrolizumab (post-systemic therapy)
Class. PD-1 inhibitor.
Dose/Time. Commonly 200 mg IV every 3 weeks or 400 mg every 6 weeks.
Purpose. Second-line in selected settings (benefit shown in Asian population trial).
Mechanism. Restores T-cell anti-tumor activity.
Side effects. Immune-related events (thyroid, liver, lung, skin). PubMedDurvalumab (monotherapy)
Class. PD-L1 inhibitor.
Dose/Time. 1500 mg IV every 4 weeks (per label/weight limits).
Purpose. Option when CTLA-4 or bevacizumab are not suitable.
Mechanism. Immune checkpoint blockade.
Side effects. Immune-related hepatitis, colitis, rash. PubMedAblation adjunct analgesics (acetaminophen within safe liver dosing)
Class. Analgesic (non-opioid).
Dose/Time. Low total daily dose with strict liver-safe maximum, as advised.
Purpose. Pain control after ablation/TACE without NSAID-related bleeding.
Mechanism. Central analgesia.
Side effects. Hepatotoxicity risk if overdosed—requires clinician guidance.Selective beta-blockers (portal pressure management in cirrhosis)
Class. Non-cancer supportive drug.
Dose/Time. Per hepatology protocol.
Purpose. Lower variceal bleeding risk before anti-VEGF treatment.
Mechanism. Reduces portal venous pressure.
Side effects. Bradycardia, fatigue—dose-titrate carefully.Antivirals for HBV (e.g., tenofovir, entecavir)
Class. Nucleos(t)ide analogs.
Dose/Time. Daily long-term; start before/with cancer therapy in eligible HBV.
Purpose. Prevent HBV reactivation and further liver injury.
Mechanism. Suppress viral replication.
Side effects. Usually mild; monitor kidneys and bone for some agents.Direct-acting antivirals for HCV
Class. Antiviral combinations.
Dose/Time. Typical 8–12 weeks, timed around oncology plan.
Purpose. Cure HCV to protect the remaining liver.
Mechanism. Blocks HCV enzymes.
Side effects. Generally mild; drug–drug checks needed.Supportive antiemetics (e.g., ondansetron) and appetite support
Class. 5-HT3 antagonists / others.
Dose/Time. Around treatment days.
Purpose. Control nausea and improve intake.
Mechanism. Blocks serotonin pathways.
Side effects. Constipation, headache—balance with diet and fluids.
(Your oncology team selects among these based on stage, liver function (Child-Pugh), bleeding risk, and BCLC/NCCN/AASLD guidance.) PMC+1PubMed
Dietary molecular supplements
Protein supplementation (whey or equivalent) – Supports muscle protein synthesis to combat sarcopenia; dose commonly 20–30 g between meals if safe for liver and sodium status; mechanism: leucine-rich amino acids stimulate mTOR; benefit: strength and function.
Branched-chain amino acids (BCAAs) – May help minimal hepatic encephalopathy and muscle; typical split doses with meals; mechanism: alternative energy substrate, ammonia handling; benefits: cognition/functional support in cirrhosis.
Vitamin D – Correct deficiency (per labs) to support bone, muscle, and immune function; mechanism: nuclear receptor modulation; benefit: fewer falls, better muscle performance.
Omega-3 fatty acids (fish oil) – Dose often 1–2 g/day EPA+DHA if not contraindicated; mechanism: anti-inflammatory eicosanoid shift; benefit: appetite and lean mass support in some cancer cachexia studies.
Thiamine (B1) – Essential in alcohol-related liver disease; dose per deficiency risk; mechanism: carbohydrate metabolism cofactor; benefit: prevents Wernicke’s and supports energy.
Zinc – If deficient in cirrhosis; mechanism: urea cycle and taste function; benefit: improved taste and possibly encephalopathy control.
Selenium – Replace only if deficient; mechanism: antioxidant enzymes; benefit: oxidative stress balance.
Probiotics (strain-specific) – Mechanism: gut barrier and ammonia metabolism; benefit: supports stool regularity and possibly encephalopathy risk in cirrhosis.
Curcumin (caution) – Anti-inflammatory signaling; only if approved by clinician to avoid interactions; benefit: symptomatic inflammation support.
Oral rehydration/electrolyte solutions – Mechanism: maintains volume with safe sodium as guided; benefit: helps during post-procedure nausea days.
Supplements can interact with TKIs and immunotherapy. Always clear each product with your oncology/pharmacy team.
Immunity booster / regenerative / stem-cell”–type drugs
There are no proven stem-cell “cures” for HCC in routine care. Below are real immune-regulatory or regenerative-supportive medical steps used in practice or trials; anything beyond this should be within clinical studies only.
HBV antivirals (tenofovir/entecavir) – Protect the liver by suppressing HBV; dose daily; function: reduce inflammation and prevent flares during cancer therapy.
HCV direct-acting antivirals – Cure HCV when appropriate; dose per regimen; function: reduce ongoing liver damage.
Immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4 combos) – Listed above; function: amplify anti-tumor immunity; dosing per protocol. PMCNew England Journal of Medicine Evidence
Hepatology-guided nutrition (protein + BCAAs if safe) – Function: supports muscle and immune resilience; dose individualized.
Portal hypertension management (nonselective beta-blockers, endoscopic variceal ligation) – Function: protects against bleeding so immunotherapy/anti-VEGF drugs can proceed more safely.
Clinical trials of cell-based or regenerative therapies – Only inside regulated trials; function: investigate future options; mechanism varies; discuss eligibility with your center.
Surgeries and procedures
Liver resection (partial hepatectomy) – Surgical removal of the tumor with a margin of normal liver. Why. Potentially curative in early HCC with good liver function and no major portal hypertension.
Liver transplantation – Replaces the whole diseased liver with a donor organ. Why. Best long-term cure for eligible patients meeting Milan criteria (single ≤5 cm or up to 3 tumors each ≤3 cm, no vascular invasion or spread). Down-staging with TACE/TARE/SBRT may help selected patients become eligible. New England Journal of MedicinePubMed
Ablation (RFA/MWA) – Destroys small tumors with heat. Why. Curative option for very early lesions or patients unfit for surgery.
Transarterial chemoembolization (TACE) – Injects chemotherapy and embolic particles into tumor-feeding arteries. Why. Standard for many intermediate-stage cases to shrink or control tumors; also used as a bridge to transplant. PMC
Transarterial radioembolization (TARE, Y-90) – Delivers targeted radiation microspheres through the hepatic artery. Why. Treats liver-confined disease, including when vessel invasion makes TACE less suitable; used for down-staging or bridging to transplant in guidelines. PMCUnivera Prospect
(External-beam radiation such as SBRT is another important local option when ablation/TACE aren’t feasible.) PMC
Prevention
Get vaccinated against hepatitis B if at risk; encourage family to vaccinate. PMC
Seek curative treatment for hepatitis C if eligible.
Avoid alcohol to protect the liver.
Maintain a healthy weight and treat diabetes to reduce fatty-liver inflammation.
Store grains and nuts safely; avoid moldy foods to reduce aflatoxin exposure. PMC
Use medicines carefully—avoid unnecessary herbal or over-the-counter products that stress the liver.
Screening if high-risk: ultrasound ± AFP every 6 months. hepatitisc.uw.edu
Manage iron overload if present (hereditary hemochromatosis) per hepatology.
Vaccinate against hepatitis A if you have chronic liver disease (prevents extra injury).
Stop smoking; it adds vascular and cancer risks.
When to see doctors urgently
New or worsening abdominal pain, fever, or jaundice (yellow eyes/skin)
Vomiting blood, black stools, or sudden swelling of the belly or legs
Severe fatigue, confusion, or sleepy/flapping hands (possible encephalopathy)
Shortness of breath, chest pain, or severe headache
After starting immunotherapy or TKIs: any new rash, diarrhea, cough/shortness of breath, or right-upper abdominal pain—these may be immune or drug side effects and need prompt care.
What to eat and what to avoid
Eat: small, frequent, protein-rich meals (eggs, fish, pulses) if your clinician approves your protein target.
Eat: whole grains, fruits, and vegetables for fiber and micronutrients.
Eat: healthy fats (olive oil, nuts, seeds) in moderate amounts.
Eat: probiotic-containing yogurt if tolerated.
Drink: enough fluids; use low-sodium options if you have fluid retention.
Avoid: alcohol completely.
Avoid: undercooked shellfish (infection risk).
Avoid: highly salted processed foods if ascites; follow your sodium plan.
Avoid: herbal products/supplements not cleared by your care team (liver toxicity and drug interactions).
Avoid: foods that are moldy or poorly stored (possible aflatoxin). PMC
FAQs
1) Can HCC be diagnosed without a biopsy?
Yes—if you have risk factors (like cirrhosis or chronic HBV) and the CT/MRI shows arterial phase hyperenhancement with portal/delayed washout and other LI-RADS features. This pattern is highly specific. PMC
2) How often should high-risk people be screened?
Every 6 months with ultrasound ± AFP. This timing balances detection and cost. hepatitisc.uw.edu
3) What are Milan criteria for transplant?
One tumor ≤5 cm or up to 3 tumors each ≤3 cm, with no major vessel invasion or spread. New England Journal of Medicine
4) What is TACE?
A catheter delivers chemo and particles into tumor arteries to block blood flow. It controls growth and can bridge to transplant. PMC
5) What is TARE (Y-90)?
Microspheres carrying radiation are injected via the hepatic artery to radiate tumors from within; useful when TACE isn’t suitable or as bridge/down-staging. PMC
6) What is SBRT?
Precisely targeted external-beam radiation over a few sessions for localized liver tumors when ablation or TACE aren’t options. PMC
7) What is the leading first-line drug therapy now?
Common first-line options include atezolizumab + bevacizumab, durvalumab + tremelimumab (STRIDE), and, since 2025 in the U.S., nivolumab + ipilimumab; TKIs (lenvatinib or sorafenib) are options if immunotherapy isn’t suitable. PMCNew England Journal of Medicine EvidenceU.S. Food and Drug Administration
8) What if those stop working?
Second-line options include regorafenib, cabozantinib, ramucirumab (if AFP ≥ 400), and pembrolizumab in selected contexts. Choice depends on prior drugs and liver status. The LancetNew England Journal of MedicineU.S. Food and Drug Administration
9) Do I need an endoscopy before starting bevacizumab?
Often yes, to check and treat varices, because bevacizumab can increase bleeding risk. (Practice varies by center.)
10) Does curing hepatitis C remove my HCC risk?
It reduces but does not eliminate risk; continue 6-monthly surveillance if you have advanced fibrosis/cirrhosis. hepatitisc.uw.edu
11) Can lifestyle changes really help?
Yes. Exercise and nutrition counseling reduce fatigue, preserve muscle, and improve treatment tolerance and quality of life. PMC
12) Are there proven stem-cell cures?
Not in routine care. Any cell-based therapy should be in a regulated clinical trial.
13) Is a biopsy always required?
No. In at-risk patients, classic multiphasic imaging can be enough; biopsy is used when imaging is atypical or uncertain. PMC
14) Can HCC be prevented?
HBV vaccination, HCV cure, safe food storage to avoid aflatoxin, avoiding alcohol, and managing metabolic syndrome lower risk. PMC+1
15) What is LI-RADS?
A standardized imaging system that classifies liver findings and treatment response, helping radiologists and oncologists communicate and plan care. Radiopaedia
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 09, 2025.
Nephronophthisis
